Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

IOVA Iovance Biotherapeutics

9.580
+0.050+0.52%
Close 09/30 16:00 ET
9.500
-0.080-0.84%
Post Mkt Price 09/30 17:21 ET
High
10.085
Open
9.460
Turnover
17.09M
Low
9.460
Pre Close
9.530
Volume
1.76M
Market Cap
1.51B
P/E(TTM)
Loss
52wk High
27.960
Shares
157.80M
P/E(Static)
Loss
52wk Low
6.180
Float Cap
1.23B
Bid/Ask %
61.54%
Historical High
165.000
Shs Float
128.16M
Volume Ratio
0.86
Historical Low
1.000
Dividend TTM
--
Div Yield TTM
--
P/B
3.20
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.37%
Amplitude
6.56%
Avg Price
9.728
Lot Size
1
Float Cap
1.23B
Bid/Ask %
61.54%
Historical High
165.000
Shs Float
128.16M
Volume Ratio
0.86
Historical Low
1.000
Dividend TTM
--
P/B
3.20
Dividend LFY
--
Turnover Ratio
1.37%
Amplitude
6.56%
Avg Price
9.728
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.
CEO: Mr. Frederick G. Vogt, J.D.,PhD
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...